Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.

Clinicoecon Outcomes Res · 2019 · PMC6900467 · PMID 31824181

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

It is worth noting that despite the large magnitude of difference in the mean hospitalization costs between brexpiprazole-treated patients and their matched quetiapine XR-treated patients (US$1,166 vs US$2,346; 50.3% lower), the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.